The biology of CD20 and its potential as a target for mAb therapy
about
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsResponse to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatmentStatins impair antitumor effects of rituximab by inducing conformational changes of CD20In silico designing, cloning, and heterologous expression of novel chimeric human B lymphocyte CD20 extra loop.Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.The potential effect of statins on rituximab immunotherapy.Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.The future of primary intraocular lymphoma (retinal lymphoma).Presence of antigen-experienced T cells with low grade of differentiation and proliferative potential in chronic Chagas disease myocarditis.Ofatumumab, a human anti-CD20 monoclonal antibody.Induction of interleukin-6 production by rituximab in human B cells.The spectrum of use of rituximab in chronic lymphocytic leukemiaCD20 antibody primes B lymphocytes for type I interferon production.Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trialRole of ofatumumab in treatment of chronic lymphocytic leukemiaThe discovery and development of belimumab: the anti-BLyS-lupus connectionSpontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigenAntibody therapeutics: isotype and glycoform selection.Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma.B Cell in Autoimmune Diseases.Treating multiple sclerosis with monoclonal antibodies.New insights into the mechanisms of action of radioimmunotherapy in lymphoma.Cancer therapeutic antibodies come of age: targeting minimal residual disease.Emerging immunopharmacological targets in multiple sclerosis.Anti-CD20 monoclonal antibodies: historical and future perspectives.The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.The future of CD20 monoclonal antibody therapy in B-cell malignancies.Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applications.Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
P2860
Q26768154-E80513C9-E66D-4ADA-8C9C-DAB2AA4FFD85Q26830569-1D05D08D-ACD5-4783-9C5B-C2B3B10D09D1Q27692640-04CEC682-FFB0-4F55-8BC5-884A580E7537Q28082086-7672FAC2-9458-4553-AD3B-97F32650E488Q28472420-5B543127-BF64-46BC-B16F-BBB1234EBEC0Q30389864-08EEDDDA-3499-4666-8C1F-8E8070546479Q30500362-EEEAB308-67A9-4145-A703-21DA5ECAAC1AQ33325581-EAB332E9-7682-430C-8A28-EB20F9ABEC5BQ33781006-FED37746-3070-44EC-9842-DCCBFB7ABB4AQ33849373-EDD5A64A-674F-4D52-8E93-EF0187DEB632Q33950795-DB665071-FDCB-4583-A092-2677465AC9D2Q34075123-A78E2F75-A8BA-4E4A-8E0A-6F577BD38B4DQ34095311-D1902ADA-A28C-47B1-BCE8-F0FA2827C7B7Q34415869-F0CCE7D1-556A-4446-B726-70497F2B45C6Q34510030-CD197581-2581-4D21-B371-884A6ED1021BQ34846171-E0E21103-50A0-480B-961E-EB9199BE94FEQ35540009-BC092CB6-ADAA-4537-A77E-322900EFAD11Q35683837-7707106D-1862-4B16-ACE6-E8E5CB655757Q35691272-2C86607F-2051-4D39-9C4A-186D8542BAE2Q35839793-ECC9CFDC-C608-4B71-B960-C33B4417DDF0Q35918821-FE02C4F3-4B96-4DE9-8D6A-3DA1DC32FD1FQ36200735-07E50783-15B5-47E8-BD22-F64F1640F5CCQ36414417-06FC6448-EFEB-43F0-B9F1-7664029336EDQ36528137-9EB772D4-0524-47F9-9F61-0E12571CCD7FQ36577391-09F71FEA-07D6-4785-9F00-DF877F95D2E6Q36777171-A22D7CF0-7464-417E-B210-46248CBF811FQ36922260-C99E93AB-CEF0-4915-8E83-E9423CF0A2F5Q36940760-77ACAC0E-76D3-4136-8B6F-0133E473B955Q36954468-66FC9503-DFE9-4A00-823C-23526C68CCB0Q37111904-207F14B8-FD08-4F37-93BD-C37D1760634CQ37222783-47E0BA47-4C0B-4994-BA8F-B4E65C6D9009Q37453793-A58BAFBE-F3E9-4A22-A57E-17A57D75070CQ37559970-FF563DB0-1473-481E-9596-58E5E6BCD6ECQ37601775-B018F630-428E-4510-A535-A7478593D1ADQ37689179-DFFDDAA9-082E-42B3-B76C-86DB2C8B0717Q37724396-143E4C3D-9972-454C-805B-C1116AF73961Q37752447-49CE3918-1829-4EA0-B3E2-216229931D43Q37782256-6E03CF22-8651-4275-9FEC-75E357CF9E69Q37799820-99138FCD-F7C0-45CB-8337-F68A0E6A0833Q37810901-A423E5CF-85C8-4987-84BD-E2FB850CA5BF
P2860
The biology of CD20 and its potential as a target for mAb therapy
description
2005 nî lūn-bûn
@nan
2005 թուականին հրատարակուած գիտական յօդուած
@hyw
2005 թվականին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The biology of CD20 and its potential as a target for mAb therapy
@ast
The biology of CD20 and its potential as a target for mAb therapy
@en
The biology of CD20 and its potential as a target for mAb therapy
@nl
type
label
The biology of CD20 and its potential as a target for mAb therapy
@ast
The biology of CD20 and its potential as a target for mAb therapy
@en
The biology of CD20 and its potential as a target for mAb therapy
@nl
prefLabel
The biology of CD20 and its potential as a target for mAb therapy
@ast
The biology of CD20 and its potential as a target for mAb therapy
@en
The biology of CD20 and its potential as a target for mAb therapy
@nl
P356
P1476
The biology of CD20 and its potential as a target for mAb therapy
@en
P2093
Claire A Walshe
Martin J Glennie
P304
P356
10.1159/000082102
P407
P577
2005-01-01T00:00:00Z